The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
catechol-O-methyltransferase inhibitor
levodopa
motor fluctuations
opicapone
Parkinson's disease
wearing-off
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/202fb31b049d40719834b2f73826e988
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/202fb31b049d40719834b2f73826e988

Ejemplares similares